EUVIMEDEUVIMED entdecken
Crossref

PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT

TWANA TAHER QADER, OTHMAN ISMAT ABDULMAJEED, ABDULQADIR M. ZANGANA

Duhok Medical Journal · 2018

DOI: 10.31386/dmj.2017.11.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Duhok Medical Journal, 2018. Verfasst von TWANA TAHER QADER und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

QADER, T. T., ABDULMAJEED, O. I., & ZANGANA, A. M. (2018). PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT. Duhok Medical Journal. https://doi.org/10.31386/dmj.2017.11.5

Vancouver

QADER TT, ABDULMAJEED OI, ZANGANA AM. PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT. Duhok Medical Journal. 2018. doi:10.31386/dmj.2017.11.5

BibTeX
@article{QADER2018,
  author = {QADER, TWANA TAHER and ABDULMAJEED, OTHMAN ISMAT and ZANGANA, ABDULQADIR M.},
  title = {PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT},
  journal = {Duhok Medical Journal},
  year = {2018},
  doi = {10.31386/dmj.2017.11.5}
}
Kostenlos starten →